Why Is TREVI THERAPEUTICS I (TRVI) Stock Up Today?

Trevi Therapeutics (TRVI) surged 11.52% to $19.36 in morning trading on Friday. The stock's sharp rise followed a late-stage trial setback for a competitive therapy in the chronic cough space. The move reflects investor optimism that Trevi's own treatment pipeline may gain a relative advantage in the market.

What Happened

TRVI opened at $18.68, already up 7.6% from the prior close, and continued to climb after news emerged that GlaxoSmithKline (GSK) had halted development of its chronic cough therapy following a late-stage trial failure. Trevi's stock rose to a session high of $20.22 before retreating to end the morning at $19.35. The stock's performance was driven by the competitive landscape shift rather than direct corporate action from Trevi. Analysts at Needham and HC Wainwright have reiterated Buy ratings on the stock, maintaining price targets of $23 and $21 respectively, though Needham recently lowered its target to $23.

What The Data Shows

The intraday session showed a volatile but upward trajectory, with the stock trading as low as $17.19 shortly after the open. Trading volume reached 4.6 million shares, more than double the 3-month average. Options activity also showed a skew toward calls, with $1.7 million in call premiums compared to zero in puts. The largest single options print was $1.2 million in call options, indicating some speculative positioning. Trevi remains unprofitable with an EPS of -0.32 for the trailing twelve months and a market cap of $2.5 billion. The stock is currently within its 52-week range of $6.55 to $20.15.

What To Watch

Investors should monitor any further updates on the competitive landscape in the chronic cough therapy segment. No earnings date is scheduled for the near term, but coverage breadth and analyst commentary will remain key indicators of market sentiment.